Page Metadata

H. Lundbeck A/S (Lundbeck)

Company Profile

H. Lundbeck A/S (Lundbeck) his a global pharmaceuticals company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer’s disease, depression, Parkinson’s disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeckl generated revenue of $2.6 billion USD in 2017.

Summary

$43.33
$43.37
10,415
$42.86 - $43.55
-20.10 %
$43.55
$42.86
3,088
1:1
$8,597.1M
$0.95
2.20 %

Corporate Information

Executive Team
Anders Gotzsche, Interim Chief Executive Officer/Chief Financial Officer and Executive Vice President
Andres Gersel Pedersen, Executive Vice Vice President: R&D
Peter Anastasiou, Executive Vice President: North America
Jacob Tolstrup, Executive Vice President: Commercial Operations
Lars Bang, Executive Vice President: Supply Operations
Palle Holm Olesen, Vice President of Investor Relations
Company IR Website
Nasdaq International Select, June 29, 2018

Company Details

REGISTERED OFFICE ADDRESS
Ottiliavej 9, DNK, 2500
HEAD OFFICE TELEPHONE
GICS INDUSTRY GROUP
Drug Manufacturers

Resources


Photo Gallery

H. Lundbeck A/S (Lundbeck)

ATBYF Logo with blue Nasdaq International Designation
Learn about the company Learn more about H. Lundbeck A/S (Lundbeck) portfolio and projects.
ATBYF Tower Image NID
Nasdaq welcomes H. Lundbeck A/S (Lundbeck) to the Nasdaq International Designation program with the company logo on the Nasdaq MarketSite in New York's Times Square.


Social Media

Scroll up